Novan Inc
F:6LUA

Watchlist Manager
Novan Inc Logo
Novan Inc
F:6LUA
Watchlist
Price: 0.001 EUR Market Closed
Market Cap: 1.3k EUR

Net Margin
Novan Inc

-128.6%
Current
-527%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-128.6%
=
Net Income
-32.1m
/
Revenue
24.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Novan Inc
F:6LUA
1.3k EUR
-129%
US
Eli Lilly and Co
NYSE:LLY
1T USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
27%
CH
Roche Holding AG
SIX:ROG
258.9B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
211.4B GBP
16%
CH
Novartis AG
SIX:NOVN
208.6B CHF
26%
US
Merck & Co Inc
NYSE:MRK
260.5B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
-126%
US
Pfizer Inc
NYSE:PFE
143.3B USD
16%
No Stocks Found

Novan Inc
Glance View

Market Cap
1.3k EUR
Industry
Pharmaceuticals

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.

6LUA Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-128.6%
=
Net Income
-32.1m
/
Revenue
24.9m
What is the Net Margin of Novan Inc?

Based on Novan Inc's most recent financial statements, the company has Net Margin of -128.6%.

Back to Top